Instituut voor Neuropathische Pijn
English articles Research & Development Zinc vinger binding SB-509 in diabetic neuropathy: positive phase II
| Zinc vinger binding SB-509 in diabetic neuropathy: positive phase II |
|
On juli 1st 2010 Sangamo BioSciences announced positive Phase 2 data from its program to develop SB-509 as a treatment for diabetic neuropathy (DN). The data was gathered from Sangamo's phase II trials that demonstrated that SB-509 treatment resulted in clinically improvements in subjects with moderate and severe DN as compared to placebo. SB-509 is an injectable plasmid encoding a DNA-binding zinc finger DNA-binding protein (ZFP) transcription factor (ZFP TF). It is designed to upregulate the endogenous expression of the gene encoding vascular endothelial growth factor (VEGF-A). VEGF-A has been demonstrated to have direct angiogenic, neurotrophic and neuroprotective properties.
In the first study, SB-509 improved regrowth of epidermal nerve fibers (ENF) in subjects undergoing a standardized injury (p-value = 0.02), and increased blood vessel growth into a healing biopsy site. Study data also demonstrated that elevated sICAM-1 levels may aid in the upfront identification of a target population of SB-509-responsive subjects and serve as a stratification variable to enable balancing of severity of vascular disease in treatment and placebo groups. Additionally, a statistically significant top line decrease in sVCAM-1 was seen in the SB-509 treated group (p-value = 0.03) compared to placebo (p-value = 0.33). sVCAM-1 and sICAM-1 are serum biomarkers of blood vessel damage and inflammatory diseases such as type 2 diabetes. The second study focused on patients with at least one unmeasurable nerve conduction velocity (NCV) who were administered SB-509 or placebo at 0, 60 and 120 Days. In subjects with clear sensory deficits (i.e. Lower Extremity Neurologic Sensory Examination (LENSE) score >10) there was a substantial benefit in the mean change in sural NCV (sNCV) from baseline at the 180 Day time point (+1.42 m/sec in the treated group; -1.14 m/sec in the placebo group, p-value = 0.07). Both studies were positive on selected surrogate endpoints, important to understand SB-509's biological effect. Detals on dosing were not given, neither on how long the patients were treated, probaly 6 months. Furthermore clinical endpoints are missing. Juli 2010, prof. dr. Jan M. Keppel Hesselink, MD, PhD Gerelateerde artikelen |